Literature DB >> 22348644

T-cell receptor retrogenic mice: a rapid, flexible alternative to T-cell receptor transgenic mice.

Matthew L Bettini1, Maria Bettini, Dario A A Vignali.   

Abstract

The T-cell receptor (TCR) is unique in its complexity. It determines not only positive (life) and negative (death) selection in the thymus, but also mediates proliferation, anergy, differentiation, cytotoxicity and cytokine production in the periphery. Through its association with six CD3 signalling chains (εγ, δε and ζζ), the TCR is capable of recognizing an extensive variety of antigenic peptides, from both pathogens and self-antigens, and translating these interactions into multiple signalling pathways that mediate diverse T-cell developmental and functional responses. The analysis of TCR biology has been revolutionized by the development of TCR transgenic mice, which express a single clonotypic T-cell population, with diverse specificities and genetic backgrounds. However, they are time consuming to generate and characterize, limiting the analysis of large numbers of TCR over a short period of time in multiple genetic backgrounds. The recent development of TCR retrogenic technology resolves these limitations and could in time have a similarly important impact on our understanding of T-cell development and function. In this review, we will discuss the advantages and limitations of retrogenic technology compared with the generation and use of TCR transgenic mice for studying all aspects of T-cell biology.
© 2012 The Authors. Immunology © 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22348644      PMCID: PMC3385026          DOI: 10.1111/j.1365-2567.2012.03574.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  66 in total

1.  Generation of functional antigen-specific T cells in defined genetic backgrounds by retrovirus-mediated expression of TCR cDNAs in hematopoietic precursor cells.

Authors:  Lili Yang; Xiao-Feng Qin; David Baltimore; Luk Van Parijs
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-30       Impact factor: 11.205

2.  Antigen-specific CD8+ T cells respond to Chlamydia trachomatis in the genital mucosa.

Authors:  Nadia R Roan; Michael N Starnbach
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

Review 3.  Development of 2A peptide-based strategies in the design of multicistronic vectors.

Authors:  Andrea L Szymczak; Dario A A Vignali
Journal:  Expert Opin Biol Ther       Date:  2005-05       Impact factor: 4.388

Review 4.  T lymphocyte tolerance: from thymic deletion to peripheral control mechanisms.

Authors:  B Stockinger
Journal:  Adv Immunol       Date:  1999       Impact factor: 3.543

5.  Production of interleukin-12 as a self-processing 2A polypeptide.

Authors:  P J Chaplin; E B Camon; B Villarreal-Ramos; M Flint; M D Ryan; R A Collins
Journal:  J Interferon Cytokine Res       Date:  1999-03       Impact factor: 2.607

6.  Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.

Authors:  Dimitrios N Vatakis; Richard C Koya; Christopher C Nixon; Liu Wei; Sohn G Kim; Patricia Avancena; Gregory Bristol; David Baltimore; Donald B Kohn; Antoni Ribas; Caius G Radu; Zoran Galic; Jerome A Zack
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-28       Impact factor: 11.205

7.  Retroviral vector-mediated expression of HoxB4 in hematopoietic cells using a novel coexpression strategy.

Authors:  H Klump; B Schiedlmeier; B Vogt; M Ryan; W Ostertag; C Baum
Journal:  Gene Ther       Date:  2001-05       Impact factor: 5.250

8.  T cell islet accumulation in type 1 diabetes is a tightly regulated, cell-autonomous event.

Authors:  Greig P Lennon; Maria Bettini; Amanda R Burton; Erica Vincent; Paula Y Arnold; Pere Santamaria; Dario A A Vignali
Journal:  Immunity       Date:  2009-10-08       Impact factor: 31.745

9.  Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity.

Authors:  Aviva Joseph; Jian Hua Zheng; Antonia Follenzi; Teresa Dilorenzo; Kaori Sango; Jaime Hyman; Ken Chen; Alicja Piechocka-Trocha; Christian Brander; Erik Hooijberg; Dario A Vignali; Bruce D Walker; Harris Goldstein
Journal:  J Virol       Date:  2008-01-09       Impact factor: 5.103

10.  Complete but curtailed T-cell response to very low-affinity antigen.

Authors:  Dietmar Zehn; Sarah Y Lee; Michael J Bevan
Journal:  Nature       Date:  2009-01-28       Impact factor: 49.962

View more
  15 in total

Review 1.  Comparative genetics: synergizing human and NOD mouse studies for identifying genetic causation of type 1 diabetes.

Authors:  John P Driver; Yi-Guang Chen; Clayton E Mathews
Journal:  Rev Diabet Stud       Date:  2012-12-28

2.  Rapid identification and expression of human TCRs in retrogenic mice.

Authors:  Maran L Sprouse; Gabriele Blahnik; Thomas Lee; Natalie Tully; Pinaki Banerjee; Eddie A James; Maria J Redondo; Matthew L Bettini; Maria Bettini
Journal:  J Immunol Methods       Date:  2016-08-31       Impact factor: 2.303

3.  Generation of T cell receptor-retrogenic mice: improved retroviral-mediated stem cell gene transfer.

Authors:  Matthew L Bettini; Maria Bettini; Maki Nakayama; Clifford S Guy; Dario A A Vignali
Journal:  Nat Protoc       Date:  2013-09-05       Impact factor: 13.491

4.  αβT cell receptors expressed by CD4(-)CD8αβ(-) intraepithelial T cells drive their fate into a unique lineage with unusual MHC reactivities.

Authors:  Hilde Cheroutre; Florence Lambolez; Sofia Mayans; Dariusz Stepniak; Sakina Palida; Alexandre Larange; Joanna Dreux; Britni Arlian; Ryo Shinnakasu; Mitchell Kronenberg
Journal:  Immunity       Date:  2014-08-14       Impact factor: 31.745

5.  Streamlined Single Cell TCR Isolation and Generation of Retroviral Vectors for In Vitro and In Vivo Expression of Human TCRs.

Authors:  Maran L Sprouse; Gabriele Blahnik; Thomas Lee; Natalie Tully; Pinaki Benarjee; Eddie A James; Maria J Redondo; Matthew L Bettini; Maria Bettini
Journal:  J Vis Exp       Date:  2017-09-10       Impact factor: 1.355

6.  Genetic engineering of hematopoietic stem cells to generate invariant natural killer T cells.

Authors:  Drake J Smith; Siyuan Liu; Sunjong Ji; Bo Li; Jami McLaughlin; Donghui Cheng; Owen N Witte; Lili Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-20       Impact factor: 11.205

7.  TCR signal strength controls the differentiation of CD4+ effector and memory T cells.

Authors:  Jeremy P Snook; Chulwoo Kim; Matthew A Williams
Journal:  Sci Immunol       Date:  2018-07-20

Review 8.  Type 1 diabetes: translating mechanistic observations into effective clinical outcomes.

Authors:  Kevan C Herold; Dario A A Vignali; Anne Cooke; Jeffrey A Bluestone
Journal:  Nat Rev Immunol       Date:  2013-04       Impact factor: 53.106

9.  Retroviral Transduction of Bone Marrow Progenitor Cells to Generate T-cell Receptor Retrogenic Mice.

Authors:  Thomas Lee; Ivan Shevchenko; Maran L Sprouse; Maria Bettini; Matthew L Bettini
Journal:  J Vis Exp       Date:  2016-07-11       Impact factor: 1.355

10.  Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer.

Authors:  Yanni Zhu; Drake J Smith; Yang Zhou; Yan-Ruide Li; Jiaji Yu; Derek Lee; Yu-Chen Wang; Stefano Di Biase; Xi Wang; Christian Hardoy; Josh Ku; Tasha Tsao; Levina J Lin; Alexander T Pham; Heesung Moon; Jami McLaughlin; Donghui Cheng; Roger P Hollis; Beatriz Campo-Fernandez; Fabrizia Urbinati; Liu Wei; Larry Pang; Valerie Rezek; Beata Berent-Maoz; Mignonette H Macabali; David Gjertson; Xiaoyan Wang; Zoran Galic; Scott G Kitchen; Dong Sung An; Siwen Hu-Lieskovan; Paula J Kaplan-Lefko; Satiro N De Oliveira; Christopher S Seet; Sarah M Larson; Stephen J Forman; James R Heath; Jerome A Zack; Gay M Crooks; Caius G Radu; Antoni Ribas; Donald B Kohn; Owen N Witte; Lili Yang
Journal:  Cell Stem Cell       Date:  2019-09-05       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.